ReviewWorld journal of gastroenterology2021
Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Synthetic lethality targets in pancreatic ductal adenocarcinoma: prevalence and limitations of liquid biopsy detection in a minority-serving cancer center.Future oncology (London, England) · 2026Article
- Long-term survival in a patient with BRCA2-mutated pleomorphic anaplastic pancreatic carcinoma treated with Olaparib maintenance therapy.Clinical journal of gastroenterology · 2026Article
- Systemic treatment of advanced pancreatic cancer: A Comprehensive Review.Journal of cancer & allied specialties · 2026Review
- Comparison of Early-, Average-, and Late-Onset Pancreatic Cancer in a Multi-Site Cancer Center: Treatment Patterns and Outcomes.Journal of patient-centered research and reviews · 2026Article
- Article
- Molecular Pathology of Pancreatic Ductal Adenocarcinoma.Cancers · 2025Review
- Article
- Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.Cancer medicine · 2025Article
- Review
- Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma.Journal of personalized medicine · 2025Review
- Review
- Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations.Clinical genitourinary cancer · 2025Article
- Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management.Journal of clinical medicine · 2025Review
- Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy.Molecular cancer therapeutics · 2025Review
- From precursor to cancer: decoding the intrinsic and extrinsic pathways of pancreatic intraepithelial neoplasia progression.Carcinogenesis · 2024Review
- Review
- Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Targeted oncology · 2024Review
- Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian.Cancers · 2024Review
- AI powered quantification of nuclear morphology in cancers enables prediction of genome instability and prognosis.NPJ precision oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer remains a leading cause of cancer-related death with few available therapies for advanced disease. Recently, patients with germline
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.